Our analysis of various myeloproliferative disorders and hematologic malignancies confirmed the high prevalence of JAK2 mutation in PV ( [100%] 53 of 53 patients) and ET ([92.31%] 35 of 37 patients), and significant prevalence in hematological malignancies including, AML sub-types (M1, M2) ([11.76%] 02 of 17 patients), ALL-L1 ( [9.09%] 01 of 11 patients, and ALL-L2 ( [16.6%] 02 of 12 patients) and CML ( [28.57%] 02 of 07 patients).Patient details and summary of results are given in the table 1.Furthermore the mutation was not detected in 90 healthy controls. Here, JAK2 is linked to essential thrombocythemia.